The Online Investor
Diagnostics M&A image Diagnostics M&A » By The Online Investor Staff, updated Sat., Oct. 31, 6:04 AM Recent mergers and acquisitions in the Diagnostics M&A category.

Slide #45. Quest Diagnostics ConVerge Diagnostic Services

Acquirer: Quest Diagnostics (NYSE:DGX)
Acquiree: ConVerge Diagnostic Services
Details: Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, announced today that it has acquired ConVerge Diagnostic Services, LLC from Water Street Healthcare Partners, a strategic investor focused exclusively on the health care industry. ConVerge is a leading full-service laboratory providing clinical, cytology and anatomic pathology testing services to patients, physicians and hospitals in New England. Financial terms of the transaction were not disclosed.

Quest Diagnostics provides diagnostic information services. Co.'s diagnostic information segment provides information based on the menu of routine, non-routine and clinical testing and anatomic pathology testing, and other diagnostic information services. Co.'s testing capabilities, includes services for the predisposition, diagnosis, treatment and monitoring of cancers and other diseases, and provides tests in several fields, including endocrinology, immunology, neurology and oncology. Co.'s diagnostic solutions provides risk assessment services for the life insurance industry, as well as provides healthcare organizations and clinicians health information technology solutions.

Quest Diagnostics SEC Filing Email Alerts Service


Open the DGX Page at The Online Investor »

Company Name: 
Quest Diagnostics, Inc.
Stock buyback: 
DGX buyback
Website: 
www.QuestDiagnostics.com
Sector: 
Diagnostics
Number of ETFs Holding DGX: 
106
Total Market Value Held by ETFs: 
$5105604.84B
Total Market Capitalization: 
$16.84B
% of Market Cap. Held by ETFs: 
30314718.20%
 

Open the DGX Page at The Online Investor (in a new window) »

Quotes delayed 20 minutes



Buy (3.30 out of 4)
49th percentile
(ranked lower than approx. 51% of all stocks covered)

Analysts' Target Price:
DGX Stock Forecast

Based on Zacks ABR data;
powered by Xignite

Diagnostics M&A - Slide 45 of 100 Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2020, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.